



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :

C12N 9/16, A61K 38/46

A1

(11) International Publication Number:

WO 95/05455

(43) International Publication Date: 23 February 1995 (23.02.95)

(21) International Application Number: PCT/NL93/00171

(22) International Filing Date: 13 August 1993 (13.08.93)

(71) Applicant (for all designated States except US): RIJKSUNIVERSITEIT TE GRONINGEN [NL/NL]; P.O. Box 72, NL-9700 AB Groningen (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): POELSTRA, Klaas [NL/NL]; Lichtboei 30, NL-9732 JB Groningen (NL). HARDONK, Machel, Josephus [NL/NL]; Troelstralaan 79, NL-9722 JG Groningen (NL). BAKKER, Winston, Willem [NL/NL]; Kerkpad 1, NL-9795 PC Wolstersum (NL). MEIJER, Dirk, Klaas, Fokke [NL/NL]; Parklaan 17, NL-9724 AN Groningen (NL).


(74) Agent: DE BRUIJN, Leendert, C.; Nederlandsch Octrooibureau, Scheveningseweg 82, P.O. Box 29720, NL-2502 LS The Hague (NL).

(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: PHARMACEUTICAL COMPOSITION COMPRISING PHOSPHATASE OR A DERIVATIVE THEREOF



(57) Abstract

The invention relates to pharmaceutical compositions suitable for treating or curing clinical complications mediated by endotoxin, including sepsis. The compositions contain components suitable for detoxifying endotoxin rendering it less deleterious to mammals such as humans, in particular to patients with reduced host-defence resistance. The invention also relates to pharmaceutical compositions suitable for stimulating bone formation, e.g. for mending broken bone or for prophylaxis or therapy of osteoporosis and pharmaceutical compositions for decreasing or inhibiting undesired bone formation. The pharmaceutical compositions according to the invention are directed at modulating phosphatase activity *in vivo*.